Literature DB >> 29509182

Seizure Induced by a Therapeutic Dose of Venlafaxine ER: A Case Report.

Chuanzhong Ye1, Megan Ninneman, Judd S Christian, Fanglin Zhang, Dominique Musselman.   

Abstract

Venlafaxine is a selective serotonin and norepinephrine reuptake inhibitor commonly used for the treatment of depression. Although listed as an adverse reaction, seizure activity associated with a therapeutic dose of venlafaxine has rarely been documented. A review of the literature reveals only 2 cases of venlafaxine-induced seizures, both of which were generalized tonic-clonic seizures in patients on doses at the higher end of the therapeutic range. We report the case of a 44-year-old woman undergoing antituberculosis therapy who suffered complex partial seizures after ingestion of a low therapeutic dose of venlafaxine extended release (ER). Her first seizure was observed soon after venlafaxine ER was titrated from 37.5 to 75 mg daily, with a total of 9 witnessed complex partial seizures. After titrating the dose of the venlafaxine ER back down to 37.5 mg daily and beginning lamotrigine anticonvulsant therapy, the patient exhibited no further seizures. The development of seizure activity under therapeutic dosing of venlafaxine should be brought to the attention of the health care prescriber. The potential for drug-drug interactions involving venlafazine, particularly in combination with multiple drugs, such as isoniazid and levofloxacin, needs to be recognized.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29509182     DOI: 10.1097/PRA.0000000000000298

Source DB:  PubMed          Journal:  J Psychiatr Pract        ISSN: 1527-4160            Impact factor:   1.325


  1 in total

1.  Spontaneous Intracerebral Hemorrhage Due to Delta Storage Pool Disease in a Patient on a Serotonin-Norepinephrine Reuptake Inhibitor.

Authors:  Annette Leibetseder; Judith Wagner; Josef Tomasits; Hans-Peter Haring; Markus Hutterer; Johannes Trenkler; Tim J von Oertzen
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.